1. Home
  2. HOFT vs CHRS Comparison

HOFT vs CHRS Comparison

Compare HOFT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hooker Furnishings Corporation

HOFT

Hooker Furnishings Corporation

HOLD

Current Price

$13.41

Market Cap

160.4M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.44

Market Cap

177.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOFT
CHRS
Founded
1924
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
160.4M
177.7M
IPO Year
1999
2014

Fundamental Metrics

Financial Performance
Metric
HOFT
CHRS
Price
$13.41
$1.44
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
35.9K
1.2M
Earning Date
04-16-2026
05-07-2026
Dividend Yield
3.79%
N/A
EPS Growth
N/A
472.00
EPS
0.10
N/A
Revenue
$278,139,000.00
N/A
Revenue This Year
$17.37
$73.08
Revenue Next Year
$9.00
$30.94
P/E Ratio
$134.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.62
$1.09
52 Week High
$18.09
$2.62

Technical Indicators

Market Signals
Indicator
HOFT
CHRS
Relative Strength Index (RSI) 37.58 55.04
Support Level $11.99 $1.34
Resistance Level $13.63 $1.46
Average True Range (ATR) 0.54 0.09
MACD -0.13 0.03
Stochastic Oscillator 5.56 85.71

Price Performance

Historical Comparison
HOFT
CHRS

About HOFT Hooker Furnishings Corporation

Hooker Furnishings Corp is a designer, marketer, and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality, and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segments: Hooker Branded segment, Domestic Upholstery segment, and All Other. It generates the majority of its revenue from the Hooker Branded segment.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: